Engineers Gate Manager’s Recursion Pharmaceuticals RXRX Stock Holding History

Engineers Gate Manager’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$656K	Buy	+213,839	New	+$826K	0.01%	1247
2025 Q4	–	Sell	-10,834	Closed	-$52.9K	–	2476
2025 Q3	$52.9K	Sell	10,834 -83,673	-89%	-$439K	﹤0.01%	2055
2025 Q2	$478K	Buy	+94,507	New	+$464K	0.01%	1500
2025 Q1	–	Sell	-46,190	Closed	-$312K	–	2516
2024 Q4	$312K	Sell	46,190 -129,205	-74%	-$869K	0.01%	1681
2024 Q3	$1.16M	Buy	175,395 +97,604	+125%	+$700K	0.02%	904
2024 Q2	$583K	Buy	77,791 +19,630	+34%	+$171K	0.01%	1155
2024 Q1	$580K	Buy	58,161 +46,790	+411%	+$521K	0.02%	1124
2023 Q4	$112K	Buy	+11,371	New	+$81.1K	﹤0.01%	1760
2022 Q2	–	Sell	-82,120	Closed	-$588K	–	2212
2022 Q1	$588K	Buy	+82,120	New	+$873K	0.02%	974

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Engineers Gate Manager's RXRX Position: Q1 2026 in Review

Engineers Gate Manager opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 213,839 shares worth $656K. The stake represents 0.01% of the portfolio and ranks #1247 among its holdings. This is a return to the name: Engineers Gate Manager previously reported a position in RXRX as recently as Q3 2025.

Engineers Gate Manager first reported a position in RXRX in Q1 2022 and has held it in 9 quarters since. The position peaked at $1.16M in Q3 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Engineers Gate Manager held 213,839 shares of Recursion Pharmaceuticals worth $656K as of Q1 2026.
Recursion Pharmaceuticals was a new Engineers Gate Manager position in Q1 2026.
Recursion Pharmaceuticals made up 0.01% of Engineers Gate Manager's portfolio in Q1 2026, its #1247 holding.
Engineers Gate Manager first reported a position in Recursion Pharmaceuticals in Q1 2022 and has held it in 9 quarters since.
Engineers Gate Manager's Recursion Pharmaceuticals position peaked at $1.16M in Q3 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.